Intuitive Surgical Sees $11.51 Billion Trading Volume Despite 38.8% Decline

On April 24, 2025, Intuitive Surgical (ISRG) saw a trading volume of $11.51 billion, marking a 38.8% decrease from the previous day. The stock price rose by 4.14%, extending its winning streak to seven consecutive days, with a total increase of 5.26% over the past week.

Intuitive Surgical reported a first-quarter revenue of $2.25 billion, reflecting a 19% year-over-year increase. This growth was driven by a 17% increase in Da Vinci procedures, with notable contributions from general surgery in the U.S. and regional markets such as India, Korea, and the U.K. The company also achieved a record number of system placements, with 367 Da Vinci systems installed in the first quarter of 2025, representing a 17% increase from the previous year.

The Ion and SP segments showed remarkable growth, with Ion procedures increasing by 58% and SP procedures by 94%. This demonstrates strong adoption and confidence in these newer segments, contributing significantly to the company’s overall growth. To support its growth trajectory, Intuitive Surgical opened two new facilities in Sunnyvale, dedicated to manufacturing and R&D for the Da Vinci and Ion systems. These facilities are expected to bolster the company’s capabilities in innovation and production.

Despite these positive developments, the company acknowledged that tariffs are expected to impact its income statement for 2025 by approximately 1.7% of revenue, with potential increases each quarter. Additionally, Intuitive Surgical faced mixed performance in capital placements outside the U.S., with financial pressures affecting markets in Germany, the U.K., and Japan. The company also expressed concerns over Chinese tariffs of 125% on imports, which could adversely affect its ability to win future tenders in China.

Looking ahead, Intuitive Surgical provided guidance for fiscal year 2025, raising its full-year procedure growth forecast to a range of 15% to 17%, up from the previous estimate of 13% to 16%. The company expects pro forma gross margins to range between 65% and 66.5% of revenue, despite potential tariff impacts and increased depreciation from new facilities. Operating expenses are projected to grow between 10% and 14% as the company continues to invest in growth and innovation initiatives.